PITTSBURGH , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference , taking place October 4-5, 2021 .

-  KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,

PITTSBURGH , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe . Mr. Goux has more than 20 years of global biotechnology

Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference . The

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21 Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21 Our wholly-owned subsidiary Jeune Aesthetics, Inc.

KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injection Initial data from this efficacy cohort of the PEARL-1 study is anticipated in 4Q21 PITTSBURGH, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal

-  New data include update from the fourth patient treated in the Phase 1/2 trial -  Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH , July 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman Sachs 42nd Annual

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million PITTSBURGH , May 10, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.